Patent ID: 8927223
Filing Date: 2015-01-06
Classification: G01N

Abstract:
1. A method of predicting response to anti-cancer treatment, the method comprising detecting an autoantibody in a test sample, wherein the test sample comprises a bodily fluid from a human patient, and wherein comparison of a level of autoantibody in the patient with a previously established relationship between level of autoantibody and likely outcome of treatment is used to predict whether the patient will respond to the anti-cancer treatment, which method comprises, (a) preparing two or more different dilutions of the test sample and carrying out the following steps (i) and (ii) in respect of each test sample dilution in order to provide a cross-titration assay based on testing two or more dilutions of a test sample against two or more dilution of antigen to form a titration curve: (b) plotting or calculating a separate curve of the amount of specific binding versus the amount of antigen for each of the two or more test sample dilutions used in step (a), (c) determining the progress of cancer or recurrence of cancer based upon the amount of specific binding between the autoantibody and the antigen for each test sample dilution at each amount of antigen tested, wherein a change in the amount of specific binding, when compared to controls, predicts that the patient will respond to the anti-cancer treatment.